Lloyd Mitchell Segal - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Role
Director
Signature
/s/ Lloyd Mitchell Segal
Issuer symbol
AKTS
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
3
Filing time
08 Jan 2026, 21:05:28 UTC
Previous filing
14 Mar 2025
Next filing
12 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Segal Lloyd Mitchell Director C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Lloyd Mitchell Segal 08 Jan 2026 0001477123

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTS Series A Redeemable Convertible Preferred Stock 08 Jan 2026 Common Stock 13,142 See Footnote F1, F3
holding AKTS Series B Redeemable Convertible Preferred Stock 08 Jan 2026 Common Stock 6,489 See Footnote F2, F3
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 32,856 $1.45 Direct F4
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 31,542 $3.66 Direct F5
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 6,571 $4.95 Direct F6
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 10,514 $10.66 Direct F7
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 18,933 $18.00 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and have no expiration date. All shares of Series A Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 Each share of Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and have no expiration date. All shares of Series B Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F3 Consists of 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.
F4 These options have vested in full.
F5 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F6 Beginning on January 1, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F7 Beginning on October 9, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F8 The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney